Contineum Therapeutics (CTNM) EBT (2023 - 2024)
Historic EBT for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$14.6 million.
- Contineum Therapeutics' EBT fell 8366.96% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 28232.73%. This contributed to the annual value of -$42.3 million for FY2024, which is 28238.24% down from last year.
- Latest data reveals that Contineum Therapeutics reported EBT of -$14.6 million as of Q4 2024, which was down 8366.96% from -$10.3 million recorded in Q3 2024.
- Over the past 5 years, Contineum Therapeutics' EBT peaked at $42.3 million during Q2 2023, and registered a low of -$14.6 million during Q4 2024.